ImmunityBio reports 700% revenue growth, expands approvals globally
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall St falls as tech losses, Middle East tensions deepen
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Has Tesla solved the self-driving puzzle? This analyst thinks so
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Micron to deliver 'another strong quarter', Goldman says
- Supermicro plans $7 billion financing to fund AI server orders
- UK's Ofcom requires tech firms to create crisis response plans
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
February 23, 2026 7:00 AM EST2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year ANKTIVA Unit Growth: 750% unit sales volume increase in 2025 compared to 2024 Global Approvals in Bladder Cancer: ANKTIVA in combination with BCG for the treatment of BCG-unresponsive NMIBC CIS with or without papillary tumors is now authorized across four major regulatory jurisdictions: United States, United Kingdom, European Union, and Saudi Arabia encompassing 33 countries in total First Approval for Lung Cancer: ANKTIVA in combination with checkpoint inhibitors approved by the... More
